New cancer drug OP-3136 enters first human tests
NCT ID NCT06784193
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have not responded to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The study will first find a safe dose, then test it alone or with other drugs. About 180 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OP-3136 (a KAT6A/B inhibitor drug)
What this could lead to
If successful, this could point toward a new treatment option for advanced breast, lung, or prostate cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. Only a small number of participants will receive it, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research South Australia
RECRUITINGAdelaide, South Australia, 5000, Australia
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
START - Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START - Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
START - San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
University Medical Center - New Orleans
RECRUITINGNew Orleans, Louisiana, 70112, United States